Liver Metastasis in Pancreatic Ductal Adenocarcinoma: Regulatory Mechanisms and Clinical Significance
Key facts
- Who runs it
- Nanjing Medical University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 300 people, planned
- Started
- 22 Oct 2026
- Expected to end
- 20 Oct 2029
- Type of study
- Observational, 2 groups
- Record updated
- 12 November 2026
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (14)Hide the full registry criteria
Who can take part
- Aged 18-80 years, regardless of sex
- Diagnosis of pancreatic ductal adenocarcinoma (PDAC) or its variants confirmed by imaging and/or pathological examination
- Meeting at least one of the following criteria:
- Liver metastasis from PDAC confirmed by contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) at initial diagnosis or during the disease course
- No evidence of liver metastasis at initial diagnosis, followed by curative-intent surgical resection and planned postoperative surveillance for liver metastasis
- Availability of sufficient clinical information, including demographic characteristics, medical history, imaging and/or pathological findings, treatment information, liver metastasis status, and follow-up outcomes
- Availability of a unique study identification code to ensure patient traceability and data linkage
- For prospective enrollment and biospecimen collection, voluntary provision of written informed consent by the patient or their legally authorized representative, as required by the approved study protocol
Who cannot take part
- Concomitant diagnosis of other malignant tumors
- Receipt of preoperative systemic antitumor therapy (neoadjuvant therapy) before curative-intent surgical resection, for patients in the resection subgroup
- Severe cardiac, pulmonary, hepatic, or renal dysfunction
- Active infectious diseases
- Severe coagulation disorders, contraindications to blood collection, or an unacceptably high risk associated with blood collection as assessed by the investigator
- Pregnancy or breastfeeding
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with a poor prognosis, and liver metastasis is a major contributor to treatment failure and reduced survival. Due to the complex mechanisms underlying tumor progression and metastasis, effective early diagnostic biomarkers and targeted therapeutic strategies remain limited. This study aims to investigate the molecular mechanisms underlying PDAC progression and liver metastasis, identify potential biomarkers for early risk prediction and prognostic assessment, and explore novel therapeutic targets to facilitate precision diagnosis and treatment.
Read full original descriptionShow less
Participants will be required to:
* Provide histopathologically confirmed primary PDAC tissue and liver metastatic tissue, together with the corresponding adjacent non-tumor pancreatic tissue * Undergo regular follow-up visits for monitoring and data collection. * Allow access to their medical records for relevant clinical information.
The 2 groups in the trial
- PDAC With Liver Metastasis
This cohort includes patients with histologically or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC) with liver metastasis confirmed by contrast-enhanced CT or MRI at initial diagnosis or during treatment. Clinical characteristics, laboratory findings, imaging data, pathological features, treatment information, and follow-up outcomes will be collected. Available biospecimens may include primary pancreatic tumor tissue, liver metastatic tissue, corresponding adjacent non-tumor pancreatic tissue, normal liver tissue, and peripheral blood samples. No study-assigned interventions will be administered, and all diagnostic and therapeutic decisions will follow routine clinical practice.
- Patients With Pancreatic Ductal Adenocarcinoma
This cohort includes patients with histologically or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC) who meet the predefined eligibility criteria. The cohort includes patients with synchronous liver metastasis at initial diagnosis and those without liver metastasis at baseline who undergo curative-intent surgical resection and are followed for the development of postoperative liver metastasis. Clinical characteristics, pathological findings, imaging data, treatment information, available biospecimens, and longitudinal follow-up outcomes will be collected. The primary outcome is the occurrence of liver metastasis within 12 months after curative-intent resection among eligible patients without liver metastasis at baseline. No study-assigned interventions will be administered, and all treatment decisions will follow routine clinical practice.
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Potential Regulatory Mechanisms Underlying the Progression of Pancreatic Ductal Adenocarcinoma and Clinical Significance: A Multicenter Exploratory Study
- Criteria questions
- Built from NCT07933952, who can take part
- Record updated
- 12 November 2026